Basit öğe kaydını göster

dc.contributor.authorOlgac, Muge
dc.contributor.authorDemir, SEMRA
dc.contributor.authorCoskun, Raif
dc.contributor.authorDeniz, Gunnur
dc.contributor.authorAktas-Cetin, Esin
dc.contributor.authorAkdeniz, Nilgün
dc.contributor.authorUnal, Derya
dc.contributor.authorErtek, Belkis
dc.contributor.authorColakoglu, Bahattin
dc.contributor.authorBuyukorturk, Suna
dc.contributor.authorGelinick, Asli
dc.date.accessioned2021-03-05T17:13:11Z
dc.date.available2021-03-05T17:13:11Z
dc.date.issued2017
dc.identifier.citationDemir S., Gelinick A., Akdeniz N., Aktas-Cetin E., Olgac M., Unal D., Ertek B., Coskun R., Colakoglu B., Deniz G., et al., "Usefulness of In Vivo and In Vitro Diagnostic Tests in the Diagnosis of Hypersensitivity Reactions to Quinolones and in the Evaluation of Cross-Reactivity: A ComprehenSive Study Including the Latest Quinolone Gemifloxacin", ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, cilt.9, ss.347-359, 2017
dc.identifier.issn2092-7355
dc.identifier.othervv_1032021
dc.identifier.otherav_c478c840-8f71-430a-ab79-d1d9ffc72cfb
dc.identifier.urihttp://hdl.handle.net/20.500.12627/130310
dc.identifier.urihttps://doi.org/10.4168/aair.2017.9.4.347
dc.description.abstractPurpose: Reports evaluating diagnosis and cross reactivity of quinolone hypersensitivity have revealed contradictory results. Furthermore, there are no reports investigating the cross-reactivity between gemifloxacin (GFX) and the others. We aimed to detect the usefulness of diagnostic tests of hypersensitivity reactions to quinolones and to evaluate the cross reactivity between different quinolones including the latest quinolone GFX. Methods: We studied 54 patients (mean age 42.31 +/- 10.39 years; 47 female) with 57 hypersensitivity reactions due to different quinolones and 10 nonatopic quinolone tolerable control subjects. A detailed clinical history, skin test (ST), and single-blind placebo-controlled drug provocation test (SBPCDPT), as well as basophil activation test (BAT) and lymphocyte transformation test (LTT) were performed with the culprit and alternative quinolones including ciprofloxacin (CFX), moxifloxacin (MFX), levofloxacin (LFX), ofloxacin (OFX), and GFX. Results: The majority (75.9%) of the patients reported immediate type reactions to various quinolones. The most common culprit drug was CFX (52.6%) and the most common reaction type was urticaria (26.3%). A quarter of the patients (24.1%) reacted to SBPCDPTs, although their STs were negative; while false ST positivity was 3.5% and ST/SBPCDPTs concordance was only 1.8%. Both BAT and LTT were not found useful in quinolone hypersensitivity. Cross-reactivity was primarily observed between LFX and OFX (50.0%), whereas it was the least between MFX and the others, and in GFX hypersensitive patients the degree of cross-reactivity to the other quinolones was 16.7%. Conclusions: These results suggest that STs, BAT, and LTT are not supportive in the diagnosis of a hypersensitivity reaction to quinolone as well as in the prediction of cross-reactivity. Drug provocation tests (DPTs) are necessary to identify both culprit and alternative quinolones.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectİmmünoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectALERJİ
dc.titleUsefulness of In Vivo and In Vitro Diagnostic Tests in the Diagnosis of Hypersensitivity Reactions to Quinolones and in the Evaluation of Cross-Reactivity: A ComprehenSive Study Including the Latest Quinolone Gemifloxacin
dc.typeMakale
dc.relation.journalALLERGY ASTHMA & IMMUNOLOGY RESEARCH
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume9
dc.identifier.issue4
dc.identifier.startpage347
dc.identifier.endpage359
dc.contributor.firstauthorID45893


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster